DBV Technologies S.A Stock-Based Compensation 2015-2025 | DBVT

DBV Technologies S.A stock-based compensation from 2015 to 2025. Stock-based compensation can be defined as the estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors

DBV Technologies S.A Stock-Based Compensation 2015-2025 | DBVT

DBV Technologies S.A stock-based compensation from 2015 to 2025. Stock-based compensation can be defined as the estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$243.4B
Amgen (AMGN)$156.3B
Gilead Sciences (GILD)$147.7B
Vertex Pharmaceuticals (VRTX)$100.1B
Bristol Myers Squibb (BMY)$97.3B
CSL (CSLLY)$85B
GSK (GSK)$80B
Regeneron Pharmaceuticals (REGN)$60B
Alnylam Pharmaceuticals (ALNY)$58B
Argenex SE (ARGX)$39.9B
BioNTech SE (BNTX)$27.1B
Insmed (INSM)$27B
Royalty Pharma (RPRX)$20.5B
Biogen (BIIB)$19.8B
Incyte (INCY)$16.8B
Illumina (ILMN)$15.4B
Genmab (GMAB)$14.7B
Genmab (GNMSF)$14.3B
Ascendis Pharma (ASND)$11.7B
BioMarin Pharmaceutical (BMRN)$11.1B
QIAGEN (QGEN)$10.9B
Moderna (MRNA)$10.4B
Exelixis (EXEL)$10.4B
Swedish Orphan Biovitrum (BIOVF)$10.3B
Verona Pharma American Depositary Share (VRNA)$9B
Exact Sciences (EXAS)$8.5B
Bio-Techne Corp (TECH)$8.4B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$8B
Halozyme Therapeutics (HALO)$7.7B